ProMIS Neurosciences, Inc. (PMN)
| Market Cap | 78.02M +213.3% |
| Revenue (ttm) | n/a |
| Net Income | -42.23M |
| EPS | -8.45 |
| Shares Out | 8.97M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,538 |
| Open | 8.29 |
| Previous Close | 8.29 |
| Day's Range | 8.00 - 8.87 |
| 52-Week Range | 6.27 - 27.40 |
| Beta | -0.25 |
| Analysts | Strong Buy |
| Price Target | 42.73 (+391.15%) |
| Est. Earnings | Nov 11, 2026 |
About PMN
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for PMN stock is "Strong Buy." The 12-month stock price target is $42.73, which is an increase of 391.15% from the latest price.
News
ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer
ProMIS Neurosciences (PMN) announced the appointment of Ivana Rubino as chief commercial officer, effective October 5. During her time at Biogen (BIIB) and F. Hoffmann-La Roche, Rubino led and helped…
ProMIS Neurosciences Appoints Seasoned Alzheimer's and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer
Former senior Biogen and Roche executive brings deep experience across Alzheimer's clinical development, launch readiness, commercialization and global medical strategy
ProMIS Neurosciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A novel antibody therapy for Alzheimer's demonstrated strong interim safety and promising biomarker engagement in a large phase I-B trial, with zero ARIA-E cases and a 15% decline in p-tau217. Top-line results are expected in Q1 2027, supported by robust funding and a differentiated technology platform.
ProMIS Neurosciences Transcript: Moody Capital Disruptive Growth & Life Science Conference
A novel antibody therapy for Alzheimer's showed zero cases of brain swelling and strong biomarker engagement in a robust phase I-B trial, with top-line results expected in Q1 2027. The differentiated approach targets only toxic protein forms, offering a safer profile than current drugs.
ProMIS Neurosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
PMN310, a differentiated antibody targeting toxic amyloid-beta oligomers, showed strong interim safety and biomarker signals in a phase I-B Alzheimer's study, with top-line results expected in Q1 2027. The company is well-funded, advancing a robust pipeline, and planning for phase III and commercial expansion.
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfol...
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
Roth Capital lowered the firm’s price target on ProMIS Neurosciences (PMN) to $29 from $30 and keeps a Buy rating on the shares. The company’s central catalyst remains the unblinded…
ProMIS Neurosciences reports Q2 EPS ($1.28), consensus ($1.90)
“The second quarter of 2026 was a pivotal period for ProMIS, as we continued to advance PRECISE-AD while maintaining a strong financial position,” said Neil Warma, President and Chief Executive…
ProMIS Neurosciences price target raised to $100 from $69 at Guggenheim
Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $100 from $69 and keeps a Buy rating on the shares. The firm cites “increased conviction” in the PMN310…
ProMIS Neurosciences Earnings Call Transcript: Q2 2026
Six-month interim data from the phase I-B PRECISE-AD trial showed a strong safety profile for PMN310, with no ARIA-E cases and favorable biomarker trends, supporting its differentiated approach in Alzheimer's. Cash runway extends through 2027, with pipeline programs advancing.
ProMIS Neurosciences Quarterly report: Q2 2026
ProMIS Neurosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
ProMIS Neurosciences Earnings release: Q2 2026
ProMIS Neurosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
Cambridge, Massachusetts, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therap...
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
Company to host investor conference call and webcast at 4:30 p.m. ET. Cambridge, Massachusetts, Aug. 03, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnolog...
ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim
Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $69 from $35 and keeps a Buy rating on the shares after the company reported positive blinded 6-month interim…
ProMIS Neurosciences price target raised to $33 from $20 at Chardan
Chardan analyst Keay Nakae raised the firm’s price target on ProMIS Neurosciences (PMN) to $33 from $20 and keeps a Buy rating on the shares. The company reported positive interim…
ProMIS Neurosciences Transcript: Study result
The blinded six-month interim analysis of the PRECISE-AD phase I-B trial showed PMN310 has a clean safety profile with no ARIA-E and only mild, asymptomatic ARIA-H, alongside favorable reductions in key Alzheimer's biomarkers p-tau217 and MTBR-tau243. Experts highlighted the potential for broader patient access and reduced monitoring needs, with final unblinded results expected in early Q1 2027.
ProMIS Neurosciences Slides: Study result
ProMIS Neurosciences has posted slides in relation to its latest quarterly earnings report, which was published on July 28, 2026.
ProMIS Neurosciences Press release: Study result
ProMIS Neurosciences issued a press release on July 28, 2026, disclosing material business information to investors.
ProMIS Neurosciences price target raised to $69 from $35 at Guggenheim
Guggenheim raised the firm’s price target on ProMIS Neurosciences (PMN) to $69 from $35 and keeps a Buy rating on the shares. ProMIS reported “positive” blinded 6-month interim safety and…
ProMIS Neurosciences’ PMN310 shows positive result in Alzheimer’s Phase 1b trial
ProMIS Neurosciences (PMN) announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial of its lead drug candidate, PMN310, in patients with mild cogni...
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1...
ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer's Disease
Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxi...
ProMIS Neurosciences initiated with a Buy at Chardan
Chardan analyst Keay Nakae initiated coverage of ProMIS Neurosciences (PMN) with a Buy rating and $20 price target The firm cites the potential of the company’s lead asset, PMN-310, targeting…
ProMIS Neurosciences reports amyloid-beta oligomer reduction by PMN310
ProMIS Neurosciences (PMN) announced the first human evidence of dose-dependent amyloid-beta oligomer reduction by its Alzheimer’s drug candidate, PMN310, presented at AAIC 2026. The findings, drawn f...